Abstract
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons which leads to muscular atrophy, paralysis and death in 3-5 years from starting symptoms. This disorder is accompanied by noteworthy spinal inflammation mediated in particular by microglia and mast cells. No effective therapy is available. This report describes the effects of administering the anti-inflammatory agent palmitoylethanolamide in a case of sporadic amyotrophic lateral sclerosis. Palmitoylethanolamide treatment led to an improved clinical picture, as evidenced by electromyographic analysis and pulmonary function. Conceivably, the action of palmitoylethanolamide could result, in part, from its ability to dampen mast cell and microglia activation.
Keywords: Mast cells, microglia, motor neuron disease, neurodegeneration, electromyography, spinal inflammation, palmitoylethanolamide, dampen mast cell, microglia activation, pulmonary function
CNS & Neurological Disorders - Drug Targets
Title:Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
Volume: 11 Issue: 7
Author(s): Simonetta Clemente
Affiliation:
Keywords: Mast cells, microglia, motor neuron disease, neurodegeneration, electromyography, spinal inflammation, palmitoylethanolamide, dampen mast cell, microglia activation, pulmonary function
Abstract: Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons which leads to muscular atrophy, paralysis and death in 3-5 years from starting symptoms. This disorder is accompanied by noteworthy spinal inflammation mediated in particular by microglia and mast cells. No effective therapy is available. This report describes the effects of administering the anti-inflammatory agent palmitoylethanolamide in a case of sporadic amyotrophic lateral sclerosis. Palmitoylethanolamide treatment led to an improved clinical picture, as evidenced by electromyographic analysis and pulmonary function. Conceivably, the action of palmitoylethanolamide could result, in part, from its ability to dampen mast cell and microglia activation.
Export Options
About this article
Cite this article as:
Clemente Simonetta, Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report, CNS & Neurological Disorders - Drug Targets 2012; 11 (7) . https://dx.doi.org/10.2174/1871527311201070933
DOI https://dx.doi.org/10.2174/1871527311201070933 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases
Current Pharmaceutical Biotechnology Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?
Current Pharmaceutical Design The Role of PGC-1α in the Pathogenesis of Neurodegenerative Disorders
Current Drug Targets The Potential Roles of Metallothionein as a Therapeutic Target for Cerebral Ischemia and Retinal Diseases
Current Pharmaceutical Biotechnology Advances in Studies on Neurodegenerative Diseases and their Treatments
Current Topics in Medicinal Chemistry Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy Early Features in Frontotemporal Dementia
Current Alzheimer Research Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-Inflammatory Agents in Parkinsons Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ultrasound-Induced Blood-Brain Barrier Opening
Current Pharmaceutical Biotechnology Amyloid β-Peptide: The Inside Story
Current Alzheimer Research RNA Metabolism in Neurodegenerative Disease
Current Chemical Biology An Insight Into Mitochondrial Dysfunction and its Implications in Neurological Diseases
Current Drug Targets Editorial [Hot Topic: Amyloid-Associated Disease Mechanisms in Alzheimers Disease (Guest Editor: Jeroen J.M. Hoozemans)]
Current Drug Targets - CNS & Neurological Disorders Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders
Current Drug Targets - CNS & Neurological Disorders